Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2019-06-26 12:47 (814 d 11:29 ago) – Posting: # 20363
Views: 1,991

Hi all,


» » If it is required, …
»
» It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

It would be an interesting lawsuit, if the company gets an RtR for lack of baseline correction and sues the FDA because the formal requirement is meaningless.
Perhaps a case where FDA could hide behind the fact that it is a draft and contains nonbinding recommendations blahblah?

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,689 posts in 4,534 threads, 1,541 registered users;
online 17 (0 registered, 17 guests [including 4 identified bots]).
Forum time: Saturday 00:17 CEST (Europe/Vienna)

Old beliefs die hard
even when demonstrably false.    E. O. Wilson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5